Literature DB >> 29664627

Nε-Acryloyllysine Piperazides as Irreversible Inhibitors of Transglutaminase 2: Synthesis, Structure-Activity Relationships, and Pharmacokinetic Profiling.

Robert Wodtke1,2,3, Christoph Hauser4, Gloria Ruiz-Gómez5, Elisabeth Jäckel1,2, David Bauer1,3, Martin Lohse1,2, Alan Wong1, Johanna Pufe1, Friedrich-Alexander Ludwig6, Steffen Fischer6, Sandra Hauser1, Dieter Greif2, M Teresa Pisabarro5, Jens Pietzsch1,3, Markus Pietsch4, Reik Löser1,3.   

Abstract

Transglutaminase 2 (TGase 2)-catalyzed transamidation represents an important post-translational mechanism for protein modification with implications in physiological and pathophysiological conditions, including fibrotic and neoplastic processes. Consequently, this enzyme is considered a promising target for the diagnosis of and therapy for these diseases. In this study, we report on the synthesis and kinetic characterization of Nε-acryloyllysine piperazides as irreversible inhibitors of TGase 2. Systematic structural modifications on 54 new compounds were performed with a major focus on fluorine-bearing substituents due to the potential of such compounds to serve as radiotracer candidates for positron emission tomography. The determined inhibitory activities ranged from 100 to 10 000 M-1 s-1, which resulted in comprehensive structure-activity relationships. Structure-activity correlations using various substituent parameters accompanied by covalent docking studies provide an advanced understanding of the molecular recognition for this inhibitor class within the active site of TGase 2. Selectivity profiling of selected compounds for other transglutaminases demonstrated an excellent selectivity toward transglutaminase 2. Furthermore, an initial pharmacokinetic profiling of selected inhibitors was performed, including the assessment of potential membrane permeability and liver microsomal stability.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29664627     DOI: 10.1021/acs.jmedchem.8b00286

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  7 in total

1.  Argininamide-type neuropeptide Y Y1 receptor antagonists: the nature of N ω-carbamoyl substituents determines Y1R binding mode and affinity.

Authors:  Jonas Buschmann; Theresa Seiler; Günther Bernhardt; Max Keller; David Wifling
Journal:  RSC Med Chem       Date:  2020-01-20

2.  Structure-activity relationships of hydrophobic alkyl acrylamides as tissue transglutaminase inhibitors.

Authors:  Alana M M Rangaswamy; Pauline Navals; Eric W J Gates; Sammir Shad; Sarah K I Watt; Jeffrey W Keillor
Journal:  RSC Med Chem       Date:  2022-01-26

3.  Application of a Fluorescence Anisotropy-Based Assay to Quantify Transglutaminase 2 Activity in Cell Lysates.

Authors:  Sandra Hauser; Paul Sommerfeld; Johanna Wodtke; Christoph Hauser; Paul Schlitterlau; Jens Pietzsch; Reik Löser; Markus Pietsch; Robert Wodtke
Journal:  Int J Mol Sci       Date:  2022-04-19       Impact factor: 6.208

4.  The Role of Transglutaminase 2 in the Radioresistance of Melanoma Cells.

Authors:  Julia Aepler; Johanna Wodtke; Robert Wodtke; Cathleen Haase-Kohn; Reik Löser; Jens Pietzsch; Sandra Hauser
Journal:  Cells       Date:  2022-04-14       Impact factor: 7.666

5.  NMR-based investigations of acyl-functionalized piperazines concerning their conformational behavior in solution.

Authors:  Robert Wodtke; Janine Steinberg; Martin Köckerling; Reik Löser; Constantin Mamat
Journal:  RSC Adv       Date:  2018-12-06       Impact factor: 4.036

6.  Investigation of Radiotracer Metabolic Stability In Vitro with CYP-Overexpressing Hepatoma Cell Lines.

Authors:  Sandy Lemm; Susanne Köhler; Robert Wodtke; Friedrich Jung; Jan-Heiner Küpper; Jens Pietzsch; Markus Laube
Journal:  Cells       Date:  2022-08-07       Impact factor: 7.666

7.  Sulfated glycosaminoglycans inhibit transglutaminase 2 by stabilizing its closed conformation.

Authors:  Claudia Damaris Müller; Gloria Ruiz-Gómez; Sophie Cazzonelli; Stephanie Möller; Robert Wodtke; Reik Löser; Joanna Freyse; Jan-Niklas Dürig; Jörg Rademann; Ute Hempel; M Teresa Pisabarro; Sarah Vogel
Journal:  Sci Rep       Date:  2022-08-03       Impact factor: 4.996

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.